N/A
N=555
Application of Economics & Social Psychology to Improve Opioid Prescribing Safety Trial 1: EHR Nudges
Opioid Abuse, Unspecified
Bottom Line
View on ClinicalTrials.gov: NCT04477304 ↗Enrolled (actual)
555
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcome: Primary: Change in Average Per-clinician Log Total Weekly MME Between Baseline and Intervention for Opioid Naïve and At-Risk Patients (Below 50 MME Daily Dose Rxs) — -0.14; -0.05 chg in avg per-clin log total weekly MME — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Opioid Naive, OR (Behavioral); At-risk for long-term use, OR (Behavioral); Long-term opioid recipient (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Southern California
- Primary completion
- Aug 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Average Per-clinician Log Total Weekly MME Between Baseline and Intervention for Opioid Naïve and At-Risk Patients (Below 50 MME Daily Dose Rxs) |
-0.14; -0.05 | <0.001 sig |
| PRIMARY Change in Average Per-clinician Log Total Weekly MME Between Baseline and Intervention for Chronic Opioid Patients (=> 50 MME Daily Dose Rxs) |
-0.21; -0.02 | <0.001 sig |
| SECONDARY Change in Average Per-clinician Weekly Proportion of Chronic Patients Prescribed a High Dose Opioid (=> 50 MME Daily Dose Rxs) Between Baseline and Intervention |
-0.08; 0 | <0.001 sig |
Summary
The opioid epidemic has had a tremendous negative impact on the health of persons in the U.S. The objective of the trial 1 of Application of Economics & Social psychology to improve Opioid Prescribing Safety (AESOPS-T1), is to discourage unnecessary opioid prescribing through the application of "behavioral insights"-empirically-tested social and psychological interventions that affect choice.
Eligibility Criteria
Inclusion Criteria
- Providers of clinics that see patients ≥ 18 years old and for whom clinic leadership agrees to participate.
Exclusion Criteria
- Visits will be excluded from intervention when the patient has active cancer.
Data sourced from ClinicalTrials.gov (NCT04477304). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.